Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: Implications for cytogenetic testing

Cancer Genetics and Cytogenetics

Volumn 198, Issue 1, 2010, Pages 71-75

  May, Philippa C ^a   Foot, Nicola ^a   Dunn, Robert ^a   Geoghegan, Helen ^a   Neat, Michael J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; PARAFFIN; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER GRADING; CANCER RELAPSE; CANCER TISSUE; CASE REPORT; CHROMOSOME 14; CHROMOSOME 8; CHROMOSOME ANALYSIS; CHROMOSOME G BAND; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE REARRANGEMENT; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE 45,X; KARYOTYPE 46,XX; KARYOTYPE 46,XY; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; GENE TRANSLOCATION; GENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; MIDDLE AGED; MOLECULAR PROBE; ONCOGENE MYC;

AGED; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOLECULAR PROBES; TRANSLOCATION, GENETIC;

EID: 77950362800     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.12.010     Document Type: Article

References (17)

1. Yoon S.O., Jeon Y.K., Kim Y.A., Kim J.E., Kim C.W. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like (GCB) type. Histopathology 2008, 53:205-217.
2. Niitsu N., Okamoto M., Miura I., Hirano M. Clinical significance of 8q24/ c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 2009, 100:233-237.
3. Klapper W., Stoecklein H., Zeynalova S., Ott G., Kosari G., Rosenwald A., Loeffler M., Trumper L., Pfreundschuh M., Siebert R. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Leukemia 2008, 22:2226-2229.
4. Savage K.J., Johnson A.J., Ben-Neriah S., Connors J.M., Sehn L.H., Farinah P., Horsman D.E., Gascoyne R.D. MYC gene re-arrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
5. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon.
6. Rosenwald A., Ott P. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol 2008, 19:iv67-iv69.
7. De Jong D. Novel lymphoid neoplasms - the borderland between diffuse large B-cell lymphoma nad Burkitt's lymphoma. Haematologica 2009, 94:894-896.
8. Tomita N., Tokunaka M., Nakamura N., Takeuchi K., Koike J., Motomura S., Miyamoto K., Kikuchi A., Hyo R., Yakushijin Y., Masaki Y., Fujii S., Hayashi T., Ishigatsubo Y., Miura I. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009, 94:935-943.
9. Niitsu N., Okamoto M., Miura i, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/ c-MYC translocations. Leukemia 2009, 23:777-783.
10. Le Gouill S., Talmant P., Touzeau C., Moreau A., Garand R., Juge-Morineau N., Gaillard F., Gastinne T., Milpied N., Moreau P., Harousseau J.L., Avet-Loiseau H. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/ c-MYC rearrangement. Haematologica 2007, 92:1335-1342.
11. Zhao X.F., Hassan A., Perry A., Ning Y., Stass S.A., Dehner L.P. C-MYC rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology. Int J Clin Exp Pathol 2008, 1:65-74.
12. Kanungo A., Medeiros L.J., Abruzzo L.V., Lin P. Lymphoid neoplasms associated with recurrent t(14;18) and 8q24/ c-MYC translocation generally have a poor prognosis. Modern Pathol 2006, 19:25-33.
13. Johnson N.A., Savage K.J., Ludkovski O., Ben-Neriah S., Woods R., Steidl C., Dyer M.J.S., Siebert R., Kuruvilla J., Klasa R., Connors J.M., Gascoyne R.D., Horsman D.E. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:2273-2279.
14. ISCN: An International System for Human Cytogenetic Nomenclature 2005, S. Karger, Basel. L.G. Schaffer, N. Tommerup (Eds.).
15. Christie L., Kernohan N., Levison D., Sales M., Cunningham J., Gillespie K., Batstone P., Meiklejohn D., Goodlad J. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator?. Leuk Lymphoma 2008, 49:470-476.
16. Einerson R.R., Law M.E., Blair H.E., Kurtin P.J., McClure R.F., Ketterling R.P., Flynn R.P., Dogan A., Remstein E.D. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia 2006, 20:1790-1799.
17. Joos S., Falk M.H., Lichter P., Haluska F.G., Henglein B., Lenoir G.M., Bornkamm G.W. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum Mol Genet 1992, 1:625-632.